Fred Alger Management LLC Increases Stake in Artivion, Inc. $AORT

Fred Alger Management LLC raised its stake in Artivion, Inc. (NYSE:AORT) by 4.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,372,572 shares of the company’s stock after acquiring an additional 55,322 shares during the period. Fred Alger Management LLC owned approximately 2.90% of Artivion worth $62,603,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in AORT. Champlain Investment Partners LLC bought a new position in Artivion during the third quarter valued at $17,912,000. Goldman Sachs Group Inc. grew its holdings in shares of Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Artivion by 235.5% during the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after acquiring an additional 313,446 shares during the period. Vanguard Group Inc. increased its holdings in Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after purchasing an additional 232,424 shares during the period. Finally, Loomis Sayles & Co. L P raised its holdings in shares of Artivion by 35.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 840,062 shares of the company’s stock valued at $38,315,000 after acquiring an additional 217,860 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a research note on Friday, April 10th. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Trading Up 1.6%

Shares of AORT stock opened at $21.41 on Wednesday. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The company has a 50-day moving average of $28.41 and a two-hundred day moving average of $36.62. The firm has a market cap of $1.04 billion, a PE ratio of 89.23 and a beta of 1.26.

Insider Buying and Selling at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.